TeloVac today reported its Phase III trial of the GV1001 vaccine in advanced metastatic pancreatic cancer did not show a significant difference in overall survival between patients who received the vaccine and control patients treated with chemotherapy.

The firm added that it identified two potential biomarkers for increased survival in response to the vaccine in a subgroup of patients, and that initial results indicated GV1001 treatment resulted in “a significant anti-inflammatory response.”

Commenting on the data, presented this week at the American Society of Clinical Oncology anunal meeting being held in Chicago, the University of Liverpool’s J.P. Neoptolemos, M.D., said: “We have identified that simultaneous vaccination with chemotherapy provides an effective method for generating both an immune response and also promoting an anti-inflammatory effect.”

Dr. Neoptolemos, who directs the Cancer Research UK Liverpool Clinical Trials Unit, added: “We are encouraged by the finding of potential biomarkers that may serve to identify a group of patients that could respond to the vaccine with improved survival. These findings are sufficiently strong to initiate new basic research into the mechanisms of action of the vaccine and test the use of GV1001 in future clinical trials aiming to improve survival of a subgroup of patients using the biomarkers identified in this trial.”

Previous articleMerck, BMS Immunotherapy Data Whets Clinical Oncology Appetite; More from ASCO
Next articleGSK Grabs MorphoSys RA Candidate in Deal Worth Up to $548M